Sign up to our newsletter

Our first COVID-19 related monoclonal antibodies will be soon available: Ten antibodies specific to SARS-CoV-2 nucleoprotein and two antibodies specific to Spike (RBD) will be launched in 2-3 weeks.

In the latest Clinical Chemistry editorial our scientist addresses an article about molecular heterogeneity of NT-proBNP/proBNP published in the same issue. In the editorial our scientist discusses the complexity of this circulating heart failure marker, current NT-proBNP assays and how ongoing research including the addressed article could affect the design of future NT-proBNP assays.

We are pleased to let you know that we are developing several monoclonal antibodies specific to SARS-CoV2 nucleoproteins (Cat.# 3CV4) and to Spike RBD (Cat.# 3CV2).

By watching this webinar, you will learn about:
- transmission and clinical characteristics of SARS-CoV-2
- the existing testing methods for SARS-CoV-2, including nucleic acid testing, genome sequencing, serological testing for SARS-CoV-2 specific antibodies and antigen testing
- the principles, advantages and limitations of these testing methods
- safety precautions for handling different types of clinical specimens for SARS-CoV-2 detection

HyTest’s SARS-CoV-2 Nucleoprotein (Cat.# 8COV3) is a full-length recombinant antigen that can be used in serology assays for the detection of COVID-19 specific antibodies.

Soluble ST2 (sST2) biomarker is used for additive risk stratification and prognosis of patients with heart failure (HF). ST2 interacts with IL-33, and IL-33/ST2 system is upregulated in cardiomyocytes and fibroblasts in response to cardiac injury or cardiac stress.

HyTest’s recombinant SARS-CoV-2 Spike RBD is now available. The antigen can be used in the development of COVID-19 serology (antibody) tests.

We are finalizing the development of SARS-CoV-2 Nucleoprotein. The antigen can be used in serology assays.

We have now developed a recombinant GFAP protein that can be used as a standard or calibrator in GFAP immunoassay development

Insulin-like growth factor binding protein-4 (IGFBP-4) fragments have been shown to predict the risk of major adverse cardiovascular events, including segment-elevation myocardial infarction, in patients with acute coronary syndrome.

We are finalizing the development of SARS-Cov-2 Spike RBD recombinant antigen.

In dogs, C-reactive protein (CRP) can be used as a marker of inflammation. Its concentration in blood increases rapidly in systemic inflammation and decreases quickly during recovery. It has been shown to increase in disorders such as bacterial infections, sepsis and pyometra, as well as in the case of post-surgical infections.

Prof. Fred S. Apple (Hennepin Healthcare/Hennepin County Medical Center, Laboratory Medicine and Pathology, and University of Minnesota School of Medicine, Minneapolis MN, US) is the winner of the 2020 IFCC Distinguished Award for Contributions to Cardiovascular Diagnostics, sponsored by HyTest. This award honors an individual who has undertaken remarkable scientific work with cardiac markers or immunodiagnostic applications to improve cardiac disease diagnosis.

We will attend the 17th China Association of Clinical Laboratory Practice Expo held at Nanchang Greenland International Expo Center, on 21-23 August.

The cardiac isoform of Troponin I (cTnI) is used as a gold standard as marker of acute myocardial infarction (AMI). The region 24-40 aar of cTnI is a perspective target for monoclonal antibodies (MAb), because it is less affected by the action of autoantibodies and is not hindered by the other components of troponin complex.

By watching this webinar, you will learn about: 
- the use of nucleic acid testing and serological testing for diagnostics of COVID-19, as well as the benefits and limitations of these methods for COVID-19 diagnostics
- the effects of SARS-CoV-2 on the cardiovascular system
- the role of cardiac and inflammatory biomarkers in distinguishing the severity and prognosis of COVID-19

The World Health Organization (WHO) declared the Coronavirus outbreak a pandemic on Wednesday, March 11, and we are very closely following the changing situation on a daily basis. We would like to confirm to you that we are continuing to supply our products as normal.

Heart failure is a severe health problem that is characterized by an increasing prevalence and economic cost.

How can we make cancer research, treatment and life with cancer better? Read more and join the contest

HyTest Shanghai has decided to cancel the opening ceremony of the new premises scheduled for the end of February 2020 due to the epidemic situation in China